Literature DB >> 30194658

Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.

Vidya C Sinha1, Helen Piwnica-Worms2.   

Abstract

Ductal carcinoma in situ (DCIS) is a non-invasive proliferative growth in the breast that serves as a non-obligate precursor to invasive ductal carcinoma. The widespread adoption of screening mammography has led to a steep increase in the detection of DCIS, which now comprises approximately 20% of new breast cancer diagnoses in the United States. Interestingly, the intratumoral heterogeneity (ITH) that has been observed in invasive breast cancers may have been established early in tumorigenesis, given the vast and varied ITH that has been detected in DCIS. This review will discuss the intratumoral heterogeneity of DCIS, focusing on the phenotypic and genomic heterogeneity of tumor cells, as well as the compositional heterogeneity of the tumor microenvironment. In addition, we will assess the spatial heterogeneity that is now being appreciated in these lesions, and summarize new approaches to evaluate heterogeneity of tumor and stromal cells in the context of their spatial organization. Importantly, we will discuss how a growing understanding of ITH has led to a more holistic appreciation of the complex biology of DCIS, specifically its evolution and natural history. Finally, we will consider ways in which our knowledge of DCIS ITH might be translated in the future to guide clinical care for DCIS patients.

Entities:  

Keywords:  Breast cancer; Ductal carcinoma in situ (DCIS); heterogeneity; tumor microenvironment

Mesh:

Year:  2018        PMID: 30194658     DOI: 10.1007/s10911-018-9410-6

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  200 in total

1.  p53 mutations and expression in breast carcinoma in situ.

Authors:  J Lukas; N Niu; M F Press
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  Diagnostic concordance among pathologists interpreting breast biopsy specimens.

Authors:  Joann G Elmore; Gary M Longton; Patricia A Carney; Berta M Geller; Tracy Onega; Anna N A Tosteson; Heidi D Nelson; Margaret S Pepe; Kimberly H Allison; Stuart J Schnitt; Frances P O'Malley; Donald L Weaver
Journal:  JAMA       Date:  2015-03-17       Impact factor: 56.272

3.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Authors:  Karla Kerlikowske; Annette M Molinaro; Mona L Gauthier; Hal K Berman; Fred Waldman; James Bennington; Henry Sanchez; Cynthia Jimenez; Kim Stewart; Karen Chew; Britt-Marie Ljung; Thea D Tlsty
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

4.  Breast field cancerization: isolation and comparison of telomerase-expressing cells in tumor and tumor adjacent, histologically normal breast tissue.

Authors:  Kristina A Trujillo; William C Hines; Keith M Vargas; Anna C Jones; Nancy E Joste; Marco Bisoffi; Jeffrey K Griffith
Journal:  Mol Cancer Res       Date:  2011-07-20       Impact factor: 5.852

5.  Multiplexed ion beam imaging of human breast tumors.

Authors:  Michael Angelo; Sean C Bendall; Rachel Finck; Matthew B Hale; Chuck Hitzman; Alexander D Borowsky; Richard M Levenson; John B Lowe; Scot D Liu; Shuchun Zhao; Yasodha Natkunam; Garry P Nolan
Journal:  Nat Med       Date:  2014-03-02       Impact factor: 53.440

Review 6.  The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.

Authors:  Sandra S McAllister; Robert A Weinberg
Journal:  Nat Cell Biol       Date:  2014-08       Impact factor: 28.824

Review 7.  Using single-cell multiple omics approaches to resolve tumor heterogeneity.

Authors:  Michael A Ortega; Olivier Poirion; Xun Zhu; Sijia Huang; Thomas K Wolfgruber; Robert Sebra; Lana X Garmire
Journal:  Clin Transl Med       Date:  2017-12-28

8.  Metabolic origins of spatial organization in the tumor microenvironment.

Authors:  Carlos Carmona-Fontaine; Maxime Deforet; Leila Akkari; Craig B Thompson; Johanna A Joyce; Joao B Xavier
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-28       Impact factor: 11.205

9.  Phylogenetic quantification of intra-tumour heterogeneity.

Authors:  Roland F Schwarz; Anne Trinh; Botond Sipos; James D Brenton; Nick Goldman; Florian Markowetz
Journal:  PLoS Comput Biol       Date:  2014-04-17       Impact factor: 4.475

Review 10.  Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance.

Authors:  Jaafar Makki
Journal:  Clin Med Insights Pathol       Date:  2015-12-21
View more
  5 in total

Review 1.  Ductal carcinoma in situ of breast: update 2019.

Authors:  Sunil S Badve; Yesim Gökmen-Polar
Journal:  Pathology       Date:  2019-08-28       Impact factor: 5.306

2.  Spatial charting of single-cell transcriptomes in tissues.

Authors:  Runmin Wei; Siyuan He; Shanshan Bai; Emi Sei; Min Hu; Alastair Thompson; Ken Chen; Savitri Krishnamurthy; Nicholas E Navin
Journal:  Nat Biotechnol       Date:  2022-03-21       Impact factor: 68.164

Review 3.  Revisiting the miR-200 Family: A Clan of Five Siblings with Essential Roles in Development and Disease.

Authors:  Vignesh Sundararajan; Ulrike C Burk; Karolina Bajdak-Rusinek
Journal:  Biomolecules       Date:  2022-06-03

4.  The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.

Authors:  Daniela Nachmanson; Adam Officer; Hidetoshi Mori; Jonathan Gordon; Mark F Evans; Joseph Steward; Huazhen Yao; Thomas O'Keefe; Farnaz Hasteh; Gary S Stein; Kristen Jepsen; Donald L Weaver; Gillian L Hirst; Brian L Sprague; Laura J Esserman; Alexander D Borowsky; Janet L Stein; Olivier Harismendy
Journal:  NPJ Breast Cancer       Date:  2022-01-13

5.  Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.

Authors:  Daniela Nachmanson; Joseph Steward; Huazhen Yao; Adam Officer; Eliza Jeong; Thomas J O'Keefe; Farnaz Hasteh; Kristen Jepsen; Gillian L Hirst; Laura J Esserman; Alexander D Borowsky; Olivier Harismendy
Journal:  BMC Med Genomics       Date:  2020-11-18       Impact factor: 3.063

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.